Vorasidenib: Insights from the INDIGO Trial Brain 11 Mins Read53 Vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant IDH1/2 enzymes, shows promise in treating grade 2 gliomas. The INDIGO trial,…
Glioma INDIGO Phase 3 Trial Vorasidenib in Patients with an IDH1 or IDH2 Mutation Brain 3 Mins Read30 Karan Dixit, MD, from Northwestern Medicine, delivered a compelling presentation during the Plenary Session at the recent conference on glioma…
